Table 2.
Demographics and laboratory findings of patients with COVID-19
| Total (n = 120) | Nonsevere group (n = 85) | Severe group (n = 35) | χ2/Z | P | |
|---|---|---|---|---|---|
| Age | 45 (16–83) | 39 (16–75) | 59 (37–83) | −5.591 | <0.001 |
| Male gender | 72 (60) | 52 (61.2) | 20 (57.1) | 0.168 | 0.682 |
| Diabetes | 12 (10) | 6 (7.1) | 6 (17.1) | 2.801 | 0.106 |
| Hypertension | 26 (21.7) | 12 (14.1) | 14 (40) | 9.785 | 0.003 |
| CAD | 7 (5.8) | 2 (2.4) | 5 (14.3) | 6.426 | 0.022 |
| COPD | 16 (13.3) | 7 (8.2) | 8 (22.9) | 4.846 | 0.036 |
| ALT | 25 (3–199) | 23 (3–199) | 34 (10–112) | −1.958 | 0.05 |
| AST | 24 (1–188) | 21 (1–188) | 36 (11–85) | −4.896 | <0.001 |
| LDH | 217.5 (123–697) | 202 (123–506) | 320 (185–697) | −6.386 | <0.001 |
| CK | 104 (26–2183) | 93 (26–1102) | 140 (28–2183) | −2.446 | 0.014 |
| PT | 12.1 (10.5–18.7) | 12 (10.5–14.4) | 12.7 (10.7–18.7) | −2.842 | 0.004 |
| APTTa | 25.1 (5.9–43.2) | 25.3 (5.9–43.2) | 24.75 (19–31.4) | −1.116 | 0.265 |
| INRb | 1.02 (0.86–1.62) | 1.02 (0.86–1.23) | 1.08 (0.91–1.62) | −3.014 | 0.003 |
| D-dimerc | 0.4 (0.05–28.49) | 0.34 (0.05–2.93) | 0.65 (0.22–28.49) | −4.653 | <0.001 |
| CRP | 8 (0.6–198) | 5 (0.7–153) | 55 (0.6–198) | −5.809 | <0.001 |
| IL-6d | 21.2 (2–118) | 3 (2–19) | 28.6 (2.69–118) | −3.416 | 0.001 |
| Ferritine | 127.5 (5.2–1580) | 84.9 (5.2–823) | 330 (30.8–1580) | −5.498 | <0.001 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; APTT, activated partial thromboplastin time; INR, international normalised ratio; CRP, C-reactive protein; PT, prothrombin time; CK, creatinine kinase; IL-6, interleukin-6.
Pearson's χ2, Fisher's exact test, Mann–Whitney U analysis. Data are n (%) or median (min-max).
a
Normal range: 21–32 sn.
b
Normal range: 0.8–1.2.
c
Normal range: <0.55 mg/l.
d
Normal range: 0–3.4 pg/dl.
e
Normal range: 10–291 μg/l.